What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Cancer
Olaf Stüve mainly investigates Multiple sclerosis, Immunology, Internal medicine, Natalizumab and Disease.
His studies deal with areas such as Clinical trial, Pathology, Central nervous system disease, Inflammation and Central nervous system as well as Multiple sclerosis.
His Central nervous system disease research incorporates elements of JC virus, Antibody and Lymphocyte.
His Internal medicine research includes elements of Interferon and Surgery.
Monoclonal and Oncology is closely connected to Progressive multifocal leukoencephalopathy in his research, which is encompassed under the umbrella topic of Natalizumab.
Olaf Stüve has included themes like Differential diagnosis, Observational study, Physical therapy and Stroke in his Disease study.
His most cited work include:
- Defining the clinical course of multiple sclerosis: The 2013 revisions (1374 citations)
- The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease (968 citations)
- Type II monocytes modulate T cell-mediated central nervous system autoimmune disease (375 citations)
What are the main themes of his work throughout his whole career to date?
Multiple sclerosis, Immunology, Internal medicine, Natalizumab and Disease are his primary areas of study.
He has researched Multiple sclerosis in several fields, including Clinical trial, Rituximab and Intensive care medicine.
His study in Immune system, T cell, Antigen, Pathogenesis and Antibody falls within the category of Immunology.
His Internal medicine research incorporates themes from Endocrinology, Surgery, Oncology and Pharmacology.
The concepts of his Natalizumab study are interwoven with issues in JC virus, Expanded Disability Status Scale, Alemtuzumab, Fingolimod and Glatiramer acetate.
His studies in Disease integrate themes in fields like Young adult, Physical therapy and Neurology.
He most often published in these fields:
- Multiple sclerosis (84.89%)
- Immunology (58.79%)
- Internal medicine (33.24%)
What were the highlights of his more recent work (between 2016-2021)?
- Multiple sclerosis (84.89%)
- Internal medicine (33.24%)
- Immunology (58.79%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Multiple sclerosis, Internal medicine, Immunology, Experimental autoimmune encephalomyelitis and Natalizumab.
The Multiple sclerosis study combines topics in areas such as Disease activity, Ocrelizumab, Clinical trial and Pharmacology.
The various areas that Olaf Stüve examines in his Internal medicine study include Gastroenterology and Oncology.
His Experimental autoimmune encephalomyelitis research is multidisciplinary, relying on both Molecular biology, T cell, Adoptive cell transfer and Autoimmunity.
His Natalizumab study combines topics from a wide range of disciplines, such as Immunosuppression, Progressive multifocal leukoencephalopathy and Intensive care medicine.
His biological study spans a wide range of topics, including Lumbar puncture, CD3, Antigen and Pathology.
Between 2016 and 2021, his most popular works were:
- High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS (73 citations)
- Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders (50 citations)
- Immunological Aspects of Approved MS Therapeutics. (43 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Cancer
His primary areas of study are Multiple sclerosis, Internal medicine, Clinical trial, Monoclonal antibody and B cell.
His Multiple sclerosis study combines topics in areas such as Neurodegeneration, Ocrelizumab, Autoimmunity, Neuroscience and CD20.
His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology and Oncology.
His research integrates issues of Intervention, Treatment options, Placebo and Intensive care medicine in his study of Clinical trial.
Olaf Stüve works mostly in the field of Monoclonal antibody, limiting it down to topics relating to Adverse effect and, in certain cases, Phases of clinical research and Antibody.
His Rituximab study is concerned with the field of Immunology as a whole.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
